Weight change associated with the use of migraine-preventive medications

被引:33
|
作者
Taylor, Frederick R. [1 ,2 ]
机构
[1] Pk Nicollet Headache Clin & Res Ctr, Minneapolis, MN 55426 USA
[2] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
关键词
antiepileptics; beta-adrenergic-receptor blockers; migraine preventive; tricyclic antidepressants; weight change;
D O I
10.1016/j.clinthera.2008.06.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Medications administered long term, such as those used for migraine prophylaxis, are often associated with weight change as a side effect. Such effects may compromise general health status, exacerbate coexisting medical conditions, and affect medication adherence. Weight gain should be of particular concern in patients with migraine, as there is evidence that overweight and obese patients with migraine are at risk for an increased frequency and severity of migraine attacks. Objective: This article reviews weight-change data from recent clinical studies of migraine-preventive medications in children, adolescents, and adults with migraine. Methods: A PubMed search was conducted for English-language articles published between January 1970 and November 2007. Among the search terms were migraine prevention, migraine prophylaxis, migraine treatment, antidepressant drug, beta-adrenergic-receptor blockers, antiepileptic drug, anticonvulsant drug, weight gain, and weight loss. Studies that reported weight-change data (gain, loss, or neutral) were included. When available, double-blind, placebo-controlled studies were selected for review. Open-label, retrospective or prospective trials may also have been included. Results: Most of the migraine-preventive medications classified by the United States Headache Consortium as group 1 based on the high level of evidence for their efficacy-for instance, amitriptyline, propranolol, and divalproex sodium-have been associated with varying degrees of weight gain. The exceptions are timolol, which is weight neutral, and topiramate, which is associated with weight loss. Among the drugs that have been associated with weight gain, a higher incidence of weight gain was observed with amitriptyline and divalproex sodium than with propranolol. Conclusion: Weight-change effects require careful consideration when selecting migraine-preventive medications, and weight should be monitored carefully over the course of any migraine treatment plan.
引用
收藏
页码:1069 / 1080
页数:12
相关论文
共 50 条
  • [1] Migraine-preventive medications: Ensuring their appropriate use
    Wenzel, Richard G.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2008, 48 (05) : E107 - E120
  • [2] Adherence to oral migraine-preventive medications among patients with chronic migraine
    Hepp, Zsolt
    Dodick, David W.
    Varon, Sepideh F.
    Gillard, Patrick
    Hansen, Ryan N.
    Devine, Emily B.
    CEPHALALGIA, 2015, 35 (06) : 478 - 488
  • [3] Efficacy and safety of telmisaltan in migraine-preventive therapy
    Akiyama, H.
    Shiraishi, M.
    Hasegawa, Y.
    JOURNAL OF HEADACHE AND PAIN, 2010, 11 : S46 - S46
  • [4] The use of migraine preventive medications among patients with and without migraine headaches
    Lafata, J. E.
    Tunceli, O.
    Cerghet, M.
    Sharma, K. P.
    Lipton, R. B.
    CEPHALALGIA, 2010, 30 (01) : 97 - 104
  • [5] Migraine preventive medications: a reappraisal
    Adelman, JU
    Brod, A
    Von Seggern, RL
    Mannix, LK
    Rapoport, AM
    CEPHALALGIA, 1998, 18 (09) : 605 - 611
  • [6] Long-Term Use and Safety of Migraine Preventive Medications
    VanderPluym, Juliana
    Evans, Randolph W.
    Starling, Amaal J.
    HEADACHE, 2016, 56 (08): : 1335 - 1343
  • [7] PrevenBox: Evaluation of concomitant use of preventive medications with OnabotulinumtoxinA in migraine
    Torres-Ferrus, Marta
    Santos Lasaosa, Sonia
    Guerrero Peral, Angel
    Lainez, Jose M.
    Viguera Romero, Javier
    Gago Veiga, Ana B.
    Irimia, Pablo
    Sanchez del Rio, Margarita
    Asskour, Laila
    Gallardo, Victor J.
    Pozo-Rosich, Patricia
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [8] INTERICTAL BURDEN OF MIGRAINE: CORRELATIONS WITH OTHER MEASURES OF MIGRAINE BURDEN AND EFFECTS OF GALCANEZUMAB MIGRAINE-PREVENTIVE TREATMENT
    Detke, Holland
    Buse, Dawn
    Ford, Janet
    Hand, Austin
    Jedynak, Jakub
    Lipton, Richard
    Port, Martha
    Sandoe, Claire
    CEPHALALGIA, 2020, 40 : 16 - 17
  • [9] Interictal Burden of Migraine: Correlations with Other Measures of Migraine Burden and Effects of Galcanezumab Migraine-Preventive Treatment
    Sandoe, Claire
    Lipton, Richard
    Buse, Dawn
    Ford, Janet
    Hand, Austin
    Jedynak, Jakub
    Port, Martha
    Detke, Holland
    NEUROLOGY, 2021, 96 (15)
  • [10] SIZING OF THE MIGRAINE POPULATION TREATED WITH PREVENTIVE MEDICATIONS FOR MIGRAINE
    Burrell, E. R.
    Mues, K. E.
    Xue, F.
    Buse, D. C.
    Lipton, R. B.
    Chia, V. M.
    VALUE IN HEALTH, 2018, 21 : S204 - S204